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Abstract
Background: The primary cause of treatment failure in medulloblastomas (MB) is the development of leptomeningeal
dissemination (seeding). For translational research on MB seeding, one of the major challenges is the development of
reliable experimental models that simulate the seeding and growth characteristics of MBs. To overcome this obstacle,
we improved an experimental mouse model by intracisternal inoculation of human MB cells and monitoring
with in vivo live images.
Methods: Human MB cells (UW426, D283 and MED8A) were transfected with a firefly luciferase gene and a
Thy1.1 (CD90.1) marker linked with IRES under the control of the CMV promoter in a retroviral DNA backbone
(effLuc). The MB-effLuc cells were injected into the cisterna magna using an intrathecal catheter, and bioluminescence
images were captured. We performed histopathological analysis to confirm the extent of tumor seeding.
Results: The luciferase activity of MB-effLuc cells displayed a gradually increasing pattern, which correlated with a
quantitative luminometric assay. Live imaging showed that the MB-effLuc cells were diffusely distributed in the
cervical spinal cord and the lumbosacral area. All mice injected with UW426-effLuc, D283-effLuc and MED8A-effLuc
died within 51 days. The median survival was 22, 41 and 12 days after injection of 1.2 × 106 UW426-effLuc, D283-effLuc
and MED8A-effLuc cells, respectively. The histopathological studies revealed that the MB-effLuc cells spread extensively
and diffusely along the leptomeninges of the brain and spinal cord, forming tumor cell-coated layers. The tumor cells
in the subarachnoid space expressed a human nuclei marker and Ki-67. Compared with the intracerebellar injection
method in which the subfrontal area and distal spinal cord were spared by tumor cell seeding in some mice,
the intracisternal injection model more closely resembled the widespread leptomeningeal seeding observed in
MB patients.
Conclusion: The results and described method are valuable resources for further translational research to
overcome MB seeding.
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Background
Medulloblastoma (MB) is a malignant childhood brain
tumor that develops in the cerebellum and brainstem.
MB commonly spreads through the cerebrospinal fluid
(CSF) and disseminates to the surfaces of the brain and
spinal cord. The overall 5-year survival rate of patients
with MB is approximately 70 % [1, 2]. Many studies have
demonstrated that tumor dissemination (seeding) into
the cerebrospinal fluid may have the strongest impact on
patient prognosis [3, 4].
Recently, genomic studies have revealed novel charac-
teristics of MBs, including molecular subtypes and driver
mutations. However, relatively little has is known about
the mechanisms of MB seeding. The paucity of meta-
static MB tissues obtained by surgical biopsy may be the
chief problem in studying MB seeding. Therefore, estab-
lishing and refining a stable MB seeding animal model
would be of great use to enhance translational research
for this clinically challenging issue.
There are many types of transgenic mouse MB
models with a high rate of spontaneous tumor devel-
opment. However, the majority of transgenic MB
mouse models develop non-disseminated tumors [5].
An MB mouse model with frequent tumor seeding
has been introduced; however, the mouse model re-
lied on random transposon mutagenesis in multiple
transgenic backgrounds, and tumor seeding was ob-
served in only 40 % of mice [6].
Tumor xenograft models using human MB cell lines
have several advantages, including technical accessibility,
short tumor growth time, and reliable development of
tumor seeding. Several methods have been described to
establish the MB seeding model and involve transplanting
human MB cells into the mouse cerebrum [7], cerebellum
[8], subdural space [9], or cisterna magna [4, 10, 11]. How-
ever, each method possesses some limitations, such as the
risks of surgical techniques, complexity of quantitative
analysis in live animals, and difficulties of precisely simu-
lating MB characteristics. Therefore, a more stable and ac-
curate method is required to establish a reliable MB
seeding model. For a long-term follow-up in vivo study,
bioluminescence imaging (BLI) provides accurate and reli-
able results about tumor growth patterns [12, 13]. BLI also
allows longitudinal follow-up for further therapeutic inter-
vention by enabling repetitive examinations [12, 13].
In this study, we demonstrated a modified xenograft
MB mouse model by injecting tumor cells into the cis-
terna magna. We monitored the MB seeding state by in
vivo live imaging using a bioluminescent signal for ac-
curate quantitative analysis. We compared the efficiency
of several widely used MB cell lines to establish MB
seeding models. The efficiency of this method to make a
MB seeding model was compared to the result using the
intracerebellar injection method. The method and
results of this study are useful resources for further
translational research on MB dissemination.
Methods
Cell cultures
Two human MB cell lines (UW426 and MED8A) were
generously provided by Dr. Young Shin Ra (Asan Medical
Center, Seoul, Korea). D283 cells were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA). UW426 and MED8A were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad,
CA) with 10 % fetal bovine serum (FBS; Invitrogen) and
1× penicillin-streptomycin (P/S; Invitrogen). D283 cells
were maintained in Eagle’s Minimum Essential Medium
(EMEM; ATCC) with 10 % FBS and 1× P/S (Invitrogen).
All cells were incubated at 37 °C in a 5 % CO2/ 95 %
air atmosphere.
Retroviral infection
MB cells (UW426, D283 and MED8A) overexpressing
the enhanced firefly luciferase gene (effLuc) were gener-
ated by retroviral infection. The DNA backbone of the
retroviral vector contained a Thy1.1 (CD90.1) marker
and the effLuc gene linked to an internal ribosome entry
site (IRES) under the control of the cytomegalovirus
(CMV) promoter. HEK293FT cells were co-transfected
with an effLuc viral vector and a DNA vector carrying
major structural proteins (GAG, Pol, and Env) using
Lipofectamine 2000 (Invitrogen). Supernatants were
collected after 48 h, filtered (0.2 μm), and added to
target MB cells with 10 mM polybrene. The infected
cells were sorted by magnetic-activated cell sorting
(MACS; Miltenyi Biotech Ltd., Bergisch Gladbach,
Germany) using a monoclonal anti-CD90.1 conjugated
to magnetic microbeads.
In vitro luciferase assay
MB-effLuc (UW426-effLuc, D283-effLuc and MED8A-
effLuc) cells were seeded into a 6-well plate, washed with
PBS, and lysed with lysis buffer (Promega, Madison,
WI). The cell lysates were collected and redistributed
into a 96-well plate. The luciferase assay was performed
using a luciferase assay kit (Promega). The biolumines-
cence intensity of each cell lysate was measured using a
microplate luminometer (GLOMAX; Promega) at an ac-
quisition time of 1 s. Each luciferase assay was performed
three times with three replicates per group.
Mouse model of MB seeding
Female BALB/c-nude mice (7–8 weeks; Orient Bio Inc.,
Seongnam, Korea) were housed under specific pathogen-
free conditions. All animal experiments were performed
at Seoul National University Hospital (SNUH) Biomed-
ical Research Institute (Seoul, Korea) with the approval
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of the Institutional Animal Care and Use Committee
(SNUH-IACUC No.14-0206-S1A2). Prior to cell injec-
tion, the mice were anesthetized with an intraperito-
neal injection of 20 mg/kg Zoletil and 10 mg/kg
xylazine. We used two different injection methods for
the MB seeding model.
First, we slowly injected the MB-effLuc cells into the
cisterna magna. MB-effLuc cells were suspended in
25 μl of PBS at different concentrations (UW426, 1.2 ×
106 cells; D283, 1.2 × 106 cells; MED8A, 1.2 × 105 to
1.2 × 106 cells). The head of the mouse was bent (at an
angle of approximately 90° to the body) in a stereotaxic
frame (Harvard Apparatus, Holliston, MA), the skin over
the posterior atlanto-occipital membrane was cut, and
the muscular layers were moved aside as previously de-
scribed [14]. The tip of a Hamilton syringe (30 gauge;
Hamilton, Reno, NV) was connected to an intrathecal
catheter (ALZET Osmotic Pumps, Cupertino, CA) and
filled with the MB-effLuc cells. The tip of the intrathecal
catheter was carefully inserted into the cisterna magna
through the posterior atlanto-occipital membrane, and
the cells were injected at a rate of 1 μl/min using an infu-
sion pump (Harvard Apparatus, Holliston, MD). The
muscular layers were realigned, and the skin was sutured.
Second, we slowly injected the UW426-effLuc (1.2 ×
105) cells through the burr hole into the right cerebellar
hemisphere (1 mm to the right of the midline, 1 mm
posterior to the coronal suture, and 3 mm deep) as pre-
viously described [8]. The mice were monitored daily for
neurologic symptoms until they were euthanized, at
which time their brains and spinal cords were removed
for histopathological analysis.
In vivo bioluminescence imaging (BLI)
For BLI acquisition, D-Luciferin (150 mg/kg, Caliper Life
Sciences, Hopkinton, MA, USA) was prepared and
injected intraperitoneally following the manufacturer’s
protocol. After anesthesia with 2 % isoflurane in 100 %
O2 through a nose cone, images were captured using an
IVIS-100 imaging system (Xenogen Corp., Alameda, CA)
every 3 days post-transplantation. Images were acquired
by integrating light for 1–3 min, and the luminescence in-
tensity in regions of interest from each image was quanti-
fied to examine the viability of the implanted cells.
Histological and immunofluorescence analysis
At the time of sacrifice, the mice were perfused with sa-
line containing 2.5 U/ml heparin and fixed with 4 %
paraformaldehyde under deep anesthesia. The brains
and spinal cords were decalcified with 10 % EDTA
(pH 7.2) for 2 weeks and dehydrated in a graded sucrose
series. The tissues were embedded in OCT compound
(Tissue-Tek®; Sakura, Tokyo, Japan) and stored at −80 °C.
Ten micron-thick frozen blocks were sagittally
sectioned using a cryostat. The sections were stained
with hematoxylin and eosin.
Sectioned tissues were immunostained with anti-
human nuclei (1:250; Millipore, Billerica, MA) and/or
anti-Ki67 (1:400; Abcam, Cambridge, UK) antibodies as
previously described [4].
Statistical analysis
Statistical significance was calculated using SPSS version
21.0 software (IBM, Armonk, NY). The survival data
were presented as Kaplan-Meier plots and analyzed by
the log-rank test. P-values < 0.05 were considered statis-
tically significant.
Results
Establishment of medulloblastoma (MB)-effLuc cells
To visualize in vivo characteristics of MB cells, three
different MB cell lines were infected with a retroviral
vector containing the enhanced firefly luciferase
(effLuc) reporter gene. The cells that possess effLuc
genes among a heterogeneous cell population were
selectively sorted by a magnetic-activated cell separ-
ator using anti-CD90.1-conjugated magnetic microbe-
ads. All MB-effLuc (UW426-effLuc, D283-effLuc and
MED8A-effLuc) cells showed significantly enhanced
luciferase signals (approximately 4, 9, 8-fold increase,
respectively) after magnetic cell sorting (Fig. 1).
MB-effLuc seeding model and survival analysis
The mouse seeding model was created by injecting the
three different MB-effLuc (UW426-effLuc, 1.2 × 106, N = 7;
D283-effLuc: 1.2 × 106, N = 8; MED8A-effLuc, 1.2 × 105,
N = 2; 3.0 × 105, N = 3; 6.0 × 105, N = 4; and 1.2 × 106, N = 4)
cells into the subarachnoid space of the cisterna magna as















































Fig. 1 Retroviral construct that contains the effLuc gene and Thy1.1
(CD90.1), linked with an internal ribosomal entry site (IRES). The luciferase
activity of effLuc cells cultured in a 96-well plate was measured using an
IVIS-100 optical imaging device. Firefly luciferase activity continuously
increased in effLuc cells in proportion to cell number
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calculated. The median survival was 22 and 41 days for
the UW426-effLuc (1.2 × 106) and D283-effLuc (1.2 ×
106) cells, respectively (Fig. 2b). After MED8A-effLuc
(1.2 × 106) cell injection, the mice began to die at 10 days
(median survival of 12 days). We changed the number
of injected MED8A-effLuc cells to determine the opti-
mal loading numbers, and the median survival was
14 days for 6.0 × 105 cells, 21 days for 3.0 × 105 cells,
and 57 days for 1.2 × 105 cells (Fig. 2b). Therefore, we
concluded that 3.0 × 105 MED8A-effLuc cells were the
optimal cell number for further studies with some
therapeutic intent.
In vivo bioluminescence imaging (BLI) of the MB-effLuc
seeding model
After intracisternal injection of MB-effLuc cells
(UW426-effLuc, 1.2 × 106; MED8A-effLuc, 3.0 × 105;
D283-effLuc, 1.2 × 106 cells, N = 5 for each group), BLI
was acquired every 3–5 days. We observed biolumin-
escence signals at day 0 in all mice (Fig. 3a). The sig-
nals spread through the spinal axis and distributed to
the lumbosacral area between day 1 and day 6 (Fig. 3a).
Photon counts in the region of interest (ROI) were
measured to quantify the BLI results. The BLI signal
in mice that were injected with MB-effLuc cells in-
creased gradually and diffused throughout the spinal
canal. Cell proliferation in MB-effLuc cell groups was
markedly enhanced after day 3 until day 16, and each
cell growth pattern was clearly discriminated with dif-
ferent luminescence between day 3 [UW426: (1.43 ±
0.66) × 106 p/s/cm2/sr; D283: (0.10 ± 0.05) × 106 p/s/
cm2/sr; MED8A: (0.10 ± 0.06) × 106 p/s/cm2/sr] and
day 16 [UW426: (4.43 ± 0.76) × 106 p/s/cm2/sr; D283:
(2.92 ± 0.78) × 106 p/s/cm2/sr; MED8A: (1.82 ± 0.11) ×
106 p/s/cm2/sr; Fig. 3b].
Histopathology of the MB seeding model
To confirm the presence of leptomeningeal tumor
seeding, mice injected with UW426-effLuc, D283-
effLuc, and MED8A-effLuc cells (N = 5 for each
group) were sacrificed at 22, 41 and 12 days, re-
spectively. Histological examination showed that
tumor cells disseminated from the subfrontal area
to the conus medullaris in mice injected with
UW426-effLuc and D283-effLuc cells (Fig. 3c and
d). Contrary to this widespread seeding pattern,
large tumor masses were observed at the MED8A-
effLuc cell injection site (Fig. 3c and d). No tumor
seeding was found in lumbosacral areas in mice
injected with MED8A-effLuc cells. Table 1 summa-
rizes the dissemination pattern of each tumor cell
group.
Tumor histology was reviewed by a neuropathologist
(Park SH). Tumors formed by MB-effLuc cell injection
consisted of a monomorphic population of small blue
cells, with a high nucleo-cytoplasmic ratio, inconspicu-
ous nucleoli, occasional cell wrapping, and frequent mi-
toses. With diffuse sheets of small, round, blue tumor
cells, the tumors corresponded to the classic subtype of
human MB. These cells developed small nucleoli
Fig. 2 Intracisternal injection for medulloblastoma (MB) seeding model and survival analysis. a Immune-deficient BALB/c-nude mice were mounted on
the stereotactic device. The mouse heads were fixed in a stereotactic device, and the cisterna magna was exposed. MB-effLuc cells (UW426-effLuc:
1.2 × 106; MED8A-effLuc: 1.2 × 105, 3.0 × 105, 6.0 × 105 and 1.2 × 106; D283-effLuc: 1.2 × 106) were slowly injected into the subarachnoid space of the
cisterna magna. b The median survival days of each group were estimated: UW426-effLuc: 22 days for 1.2 × 106 cells; D283-effLuc: 41 days for 1.2 × 106
cells; MED8A-effLuc: 57 days for 1.2 × 105 cells, 21 days for 3.0 × 105 cells, 14 days for 6.0 × 105 cells and 12 days for 1.2 × 106 cells
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(micronucleoli), scanty cytoplasm, and only subtle signs
of differentiation. In accordance with the monomorphic
nature of the cells, they maintained uniform morphology
and neuropil-type stroma after extensive in vivo growth
and spread along the leptomeninges (Fig. 3c and d). Im-
munofluorescence images revealed that the injected cells
were widespread along the pial surface of the spinal
cord, and they strongly expressed Ki-67 (Fig. 3e).
Comparison of intracisternal injection with the
intracerebellar injection method
Intracisternal (1.2 × 106 cells, N = 7) and intracerebellar
injections (1.2 × 105 cells, N = 5) using UW426-effLuc
cells were performed. In mice that had injections into
the cisterna magna, BLI signals were observed at day 0
and gradually spread along the spinal axis over time [day
0: (0.91 ± 0.49) × 106 p/s/cm2/sr; day 16, (4.43 ± 0.76) ×
106 p/s/cm2/sr; Fig. 4a and c]. However, in mice that had
injections into the cerebellar hemisphere, the signals
were detected on day 9 [(0.16 ± 0.19) × 106 p/s/cm2/sr],
suddenly increased and migrated to the spinal cord from
day 16 [(1.11 ± 0.21) × 106 p/s/cm2/sr; Fig. 4b and c].
The median survival was 22 days for the intracisternal
injection model and 34 days for the intracerebellar injec-
tion model (Fig. 4d). To analyze the histopathology, mice
that had injections into the cisterna magna (N = 5) were
sacrificed at 22 days and mice that had injections into
the cerebellar hemisphere (N = 5) were sacrificed at
Fig. 3 Bioluminescence imaging (BLI) and histological analysis for the evaluation of medulloblastoma (MB) seeding. (A and B) After injection of
the MB-effLuc cells (UW426, 1.2 × 106; D283, 1.2 × 106; MED8A, 3.0 × 105), firefly luciferase BLI was evaluated and quantified at the indicated days.
(C) Representative longitudinal sections of the brains and spinal cords of the mice with saline (control) or MB-effLuc cells (hematoxylin & eosin
stain) (1.25×). (D) Inlet figures denote the subfrontal area (a), cerebellum (b), upper thoracic spinal cord (c), lower thoracic spinal cord (d), and
conus medullaris (e). Scale bars represent 50 μm. (E) Representative immunofluorescence images (DAPI: blue, Human Nuclei: green, Ki67: red)
show that the MB-effLuc cells are highly proliferative in vivo. Scale bars represent 50 μm
Table 1 Dissemination pattern of tumor seeding in each cell
line group
Cell type UW426-effLuc D283-effLuc MED8A-effLuc
Subfrontal area 5/5 (100 %) 5/5 (100 %) 1/3 (33 %)
Cerebellum 5/5 (100 %) 5/5 (100 %) 3/3 (100 %)
Upper thoracic spinal cord 5/5 (100 %) 5/5 (100 %) 3/3 (100 %)
Lower thoracic spinal cord 5/5 (100 %) 5/5 (100 %) 1/3 (33 %)
Conus medullaris 4/5 (80 %) 5/5 (100 %) 0/3 (0 %)
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35 days. In the intracisternal injection model, tumor cells
spread in the entire neuraxis from the subfrontal area and
cerebellar surface to the distal spinal cord. In the intracer-
ebellar injection model, tumor cells aggregated in the
cerebellum and did not disseminate into the subfrontal
area or distal spinal cord in some animals examined
(Fig. 4e). Table 2 summarizes the dissemination pattern of
each cell injection method. Immunofluorescence staining
revealed that abundant human nuclei and Ki67 double
positive cells were observed in mice that had injections
into the cisterna magna or cerebellar hemisphere (Fig. 4f).
Discussion
Because tumor seeding is the most troublesome problem
in the treatment of human MBs, we have an urgent need
to develop novel therapeutics to prevent or eliminate
tumor seeding in these patients. Therefore, the establish-
ment of an effective MB seeding model and the evalu-
ation of the extent of tumor spread in live conditions are
essential for studies on innovative therapeutics. For MB
xenograft mouse models, four different injection routes
have been introduced: intracerebral, subdural, intracere-
bellar, and intracisternal [4, 7, 9, 10]. Intracerebral and
subdural (into the supratentorial subdural space) injections
of MB cells have inherent limitations to identify MB
Fig. 4 The intracisternal injection and intracerebellar injection methods. (A) BLI of mice with cell injection into the cisterna magna show that the
signals are observed at day 0, expand at day 6, and begin to spread to the spinal cord at day 9. (B) The signals were detected first at day 6 and
gradually migrated to the spinal cord from day 12 in mice with cells injected into the cerebellum. (C) BLI quantification of tumor-occupied areas
during the study. (D) The median survival was 22 and 34 days in the intracisternal injection model and intracerebellar injection model, respectively. (E)
Histopathology of xenograft MB seeding. Inlet figures denote the subfrontal area (a), cerebellum (b), upper thoracic spinal cord (c), lower thoracic spinal
cord (d), and conus medullaris (e). The intracisternal injection model displays strong similarity to the histopathological character and widespread
dissemination pattern of MB seeding. (F) Representative immunofluorescence images (DAPI: blue, Human Nuclei: green, Ki-67: red, Merge: yellow)
show that both the intracisternal- and intracerebellar-injected UW426-effLuc cells are highly proliferative in vivo. Scale bars represent 50 μm
Table 2 Dissemination pattern of tumor seeding location by
injection methods




Subfrontal area 5/5 (100 %) 1/5 (20 %)
Cerebellum 5/5 (100 %) 4/5 (80 %)
Upper thoracic spinal cord 5/5 (100 %) 5/5 (100 %)
Lower thoracic spinal cord 5/5 (100 %) 3/5 (60 %)
Conus medullaris 4/5 (80 %) 3/5 (60 %)
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characteristics in vivo because MB develops in or around
the cerebellum and spreads via subarachnoid spaces. Intra-
cerebellar MB xenograft models can be a good alternative.
This model was used in many studies for the preclinical
evaluation of medications for MB tumor cells in vivo [8].
One problem of intracerebellar injection can be an over-
growth of tumor masses and early death of mice before ad-
equate tumor seeding develops. Intracisternal cell injection
can circumvent this problem because the injected tumor
cells readily disseminate through the CSF into the distant
subarachnoid space. In the present study, a comparison of
the intracerebellar and intracisternal injection methods
using the same cell line revealed that tumor seeding was in-
complete in some mice with intracerebellar cell injection
despite the longer incubation period for the intracerebellar
injection method.
In our previous study, we injected D283 MB cells la-
beled with fluorescent magnetic nanoparticles into the cis-
terna magna and monitored tumor seeding with in vivo
live imaging [4]. Injection into the cisterna magna using a
30-gauge needle is a fastidious surgical technique that al-
lows control over the injection speed. Although the fluor-
escent signals were quantifiable by measuring the area of
signal intensity, the result was less sensitive in long-term
observations because the signals decreased as tumor cells
proliferated [12, 15–17]. To overcome these problems of
previous seeding models, we established MB-effLuc cells
and injected the cells into the cisterna magna using an
intrathecal catheter. Intrathecal catheterization via the cis-
tern magna was used for injection to the spinal fluid [18].
Bioluminescence images (BLI) were obtained every 3 days,
and live mice were monitored until a humane endpoint
when serious clinical symptoms of tumor seeding had de-
veloped. The signals increased and spread from the injec-
tion site to the distal spinal cord, confirming the
establishment of stable MB seeding models.
We also compared the seeding pattern and median
survival rates in 3 commonly used MB cell lines. The
median survival was 22 and 41 days in UW426-effLuc
(1.2 × 106) and D283-effLuc (1.2 × 106) cells, respectively.
For MED8A-effLuc cells, the median survival was too
short to apply further therapeutics with the same num-
ber of cells (1.2 × 106). Therefore, a reduction in injec-
tion number to 3.0 × 105 (median survival of 21 days)
was necessary. In brain tumor xenograft models, setting
the proper survival time is important for testing novel
therapeutics. Shortening the median survival time may
not provide sufficient intervention time, whereas overex-
tension may be laborious and time-consuming. It is also
not recommended to increase the number of cells in the
seeding model to save tumor growth time. This method
may result in the early death of the mice due to the
compressive effect of tumor masses before the cells
spread sufficiently through the CSF. Especially for the
MB seeding model, the appropriate number of cells and
injection site are important for widespread tumor seeding
along the neuraxis while allowing the mice to survive.
Conclusions
In this study, we confirmed that intracisternal injection
of MB cells exhibited stronger similarity to the dissemin-
ation pattern of MB. Furthermore, we proposed several
modifications to improve the technique of the MB seed-
ing model and provided high-throughput in vivo im-
aging. The method and cell injection numbers described
here are useful resources for future translational re-
search of MB seeding.
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